Patent US4235914A successfully refreshed from Google Patents.
US4235914A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Psychotropic γ-(heterocyclic substituted) butyrophenones
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1978-10-17
•
Granted: 1980-11-25
•
Expires: 1998-10-17
Abstract
Abstract Butyrophenone compounds having excellent psychotropic activity and represented by the formula: ##STR1## wherein Z is defined hereinbelow.
Inventors
- 👤 Kikuo Sasajima
- 👤 Keiichi Ono
- 👤 Hisao Yamamoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 04:53
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/10; C07D295/104; C07D295/108; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/30; C07D211/32; C07D211/36; C07D211/40; C07D211/44; C07D211/52
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
9 words
γ-[4-(3-Trifluoromethylphenyl)-4-hydroxypiperidino]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
9 words
γ-[4-(3-Trifluoromethylphenyl)-4-hydroxypiperidino]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
9 words
γ-[4-(2-Keto-1-benzimidazolinyl)piperidin-1-yl]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim
9 words
γ-[4-(2-Keto-1-benzimidazolinyl)piperidin-1-yl]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
9 words
γ-[4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]-decan-8-yl]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
9 words
γ-[4-Oxo-1-phenyl-1,3,8-triazaspiro[4,5]-decan-8-yl]-2-hydroxy-4-fluorobutyrophenone, or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim
41 words
An antipsychotic composition comprising an effective antipsychotic amount of at least one of the compounds as claimed in any one of claims 1, 2 or 3 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent or carrier.
Claim 8
Independent Claim
33 words
A method of treating a patient suffering from mental disease which comprises administering to said patient an effective psychotropic amount of a compound according to any one of claims 1, 2 or 3.
Claim 9
Dependent Claim
22 words
The method according to claim 5, wherein from 1 to 200 mg. of said compound is administered orally to the patient daily.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-11-25 | 1984-05-26 | 1984-11-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-11-25 | 1988-05-26 | 1988-11-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-11-25 | 1992-05-26 | 1992-11-25 | $7700.00 | Window Closed / Lapsed |